

AGENDA

Time	Presentation	Speaker
8:00 AM	Registration	
8:15 AM	Welcome: Announcements and Introductions	Nestor F. Esnaola, MD, MPH, MBA, FACS
8:30 AM	Role of Genomics in Multiple Myeloma	Nikhil C. Munshi, MD
9:15 AM	Question and Answer	
9:25 AM	Overview of Advances in Multiple Myeloma	Siddhartha Ganguly, MD, FACP
9:55 AM	Question and Answer	
10:00 AM	Break and Exhibits	
10:25 AM	Basic and Translational Research Updates in Multiple Myeloma	Qing Yi, MD, PhD
10:55 AM	Question and Answer	
11:00 AM	Supportive Care in Myeloma	Rebecca Lu, MSN, FNP-C
11:30 AM	Question and Answer	
11:35 AM	LUNCH KEYNOTE: Climate Change and Cancer	Joan H. Schiller, MD
12:35 PM	Lunch and Exhibits	
1:00 PM	SOLID TUMOR KEYNOTE: Overview of Cancer Chemoprevention	Ming You, MD, PhD
1:45 PM	Question and Answer	
1:55 PM	Management of Prostate Cancer 2022	Eleni Efstathiou, MD, PhD
2:25 PM	Question and Answer	
2:30 PM	Break and Exhibits	
2:45 PM	Breast Cancer Radiotherapy and Quality	Waqar M. Haque, MD
3:15 PM	Question and Answer	
3:20 PM	Break and Exhibits	
3:40 PM	Abstract Winner Discussions	
4:30 PM	Question and Answer	
4:45 PM	Adjournment	

PROGRAM OVERVIEW

This annual symposium, dedicated to the science and clinical care of solid and hematologic malignancies, brings together Houston Methodist scientists and physicians from a broad spectrum of fields, including basic, clinical and epidemiological research. A wide range of topics will be covered, from innovative translational science to clinical updates with strategies for implementation in current clinical practice. The program will provide education focused on improving patient care, research collaboration and leading medicine.

TARGET AUDIENCE

Physician scientists, practicing oncologists, advanced nurse practitioners and physician assistants, oncology nurses, residents, fellows, medical students, allied health personnel and clinical research associates will benefit from this course.

EDUCATIONAL OBJECTIVES

Upon completion of this course, the participant should be able to:

- Describe the role of genomics in multiple myeloma
- Discuss new modalities of therapy in multiple myeloma
- Discuss the importance of supportive care in patients with multiple myeloma

NURSING OUTCOMES STATEMENT

Oncology Nurses and Advanced Practice Nurses attending this activity will be better prepared to examine nursing implications of new cancer therapies, particularly those associated with multiple myeloma, provide high quality evidence-based care and accurate anticipatory guidance and education to patients with cancer.

EDUCATIONAL METHODS

Didactic Lectures, Question and Answer Sessions

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

Physicians

Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 6.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Houston Methodist will provide 5.91 contact hours for this activity. Participants must attend the activity in its entirety and complete the corresponding evaluation.

HOW TO RECEIVE YOUR CERTIFICATE

Complete the evaluation for this activity at <https://learn.houstonmethodist.org/cancer-symposium-2022>. Once you complete the evaluation you will be prompted to claim your credit and print/download your certificate.

CONTACT INFORMATION

Office of Continuing Medical Education
Houston Methodist Hospital
6670 Bertner Avenue, R2-216
Houston, TX 77030

Phone: 713.441.4971
Fax: 713.441.0589
Email: cme@houstonmethodist.org

DISCLAIMER AND DISCLOSURES

Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC) and Accreditation Council for Pharmacy Education (ACPE) guidelines, Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

All the relevant financial relationships listed for these individuals have been mitigated.

Name	Role(s)	Relevant Financial Relationship(s)
Eleni Efstathiou, MD, PhD	Speaker	Advisor: Astra Zeneca, Bayer, Janssen, Merck, Myovant, Pfizer, Sanofi
Siddhartha Ganguly, MD, FACP	Speaker	Advisor: AstraZeneca, Bristol Myers Squibb
Nikhil C. Munshi, MD	Speaker	Consultant: AbbVie, Amgen, BMS, GSK, Janssen, Legend, Novartis, Pfizer, Takeda Consultant: Celgene (Relationship Has Ended) Ownership Interest: Oncopep
Joan H. Schiller, MD	Speaker	Independent Data Monitoring Committee (IDMC): AstraZeneca, Genetech/Roche, Merck Research Support (Market Research): First Thought

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.

EXHIBITORS

We gratefully acknowledge the following companies for participating as exhibitors for this activity:

AbbVie	Gilead
Astellas Pharma	Incyte Corporation
AstraZeneca	Merck
BeiGene	Millennium Pharmaceuticals
BTG Specialty Pharma	Morphosys
Caris Life Sciences	Pfizer
CTI Biopharma	Pharmacyclics (PCYC)
Eisai	Regeneron
Eli Lilly and Company	Rigel Pharmaceuticals
Exact Sciences	Sanofi-Genzyme
Exelixis	Taiho